基于胰高血糖素样肽-1的疗法：不确定性的困境。 - Suppr

Suppr

超能文献

GLP-1-based therapies: the dilemma of uncertainty.

作者信息

Spranger Joachim, Gundert-Remy Ursula, Stammschulte Thomas

出版信息

Gastroenterology. 2011 Jul;141(1):20-3. doi: 10.1053/j.gastro.2011.05.019.

DOI:10.1053/j.gastro.2011.05.019

PMID:21723985

Abstract

摘要

相似文献

GLP-1-based therapies: the dilemma of uncertainty.基于胰高血糖素样肽-1的疗法：不确定性的困境。

Gastroenterology. 2011 Jul;141(1):20-3. doi: 10.1053/j.gastro.2011.05.019.

Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4?脂肪因子二肽基肽酶-4的促炎或抗炎特性？

Gastroenterology. 2011 Dec;141(6):e17. doi: 10.1053/j.gastro.2011.08.053. Epub 2011 Oct 27.

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.胰脏炎、胰脏癌与甲状腺癌与 GLP-1 类药物治疗

Gastroenterology. 2011 Jul;141(1):150-6. doi: 10.1053/j.gastro.2011.02.018. Epub 2011 Feb 18.

Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting.门诊环境中使用胰高血糖素样肽-1 受体激动剂或二肽基肽酶-4 抑制剂的患者中淀粉酶和脂肪酶水平升高。

Endocr Pract. 2012 Jul-Aug;18(4):472-7. doi: 10.4158/EP11290.OR.

The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits.GLP-1 类药物治疗相关的胰腺炎和胰腺癌风险远远低于其已证实和潜在的（心血管）获益。

Diabet Med. 2013 Oct;30(10):1148-55. doi: 10.1111/dme.12301.

Exenatide and sitagliptin: pancreatitis and pancreatic cancer. Harms on the rise.艾塞那肽和西他列汀：胰腺炎与胰腺癌。危害在增加。

Prescrire Int. 2011 Nov;20(121):267.

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.肠促胰岛素系统：2型糖尿病中的胰高血糖素样肽-1受体激动剂和二肽基肽酶-4抑制剂

Lancet. 2006 Nov 11;368(9548):1696-705. doi: 10.1016/S0140-6736(06)69705-5.

An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology.分析影响胰腺病理的肠促胰岛素作用的受检者特征。

Diabetes Technol Ther. 2013 Aug;15(8):609-18. doi: 10.1089/dia.2013.0177. Epub 2013 Aug 8.

Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide.病例报告：西格列汀与艾塞那肽联合治疗相关的急性坏死性胰腺炎。

Endocr Pract. 2012 Jan-Feb;18(1):e10-3. doi: 10.4158/EP11264.CR.

Two drugs for type 2 diabetes seem to raise risk of acute pancreatitis, study shows.研究表明，两种用于治疗2型糖尿病的药物似乎会增加急性胰腺炎的风险。

BMJ. 2013 Feb 27;346:f1304. doi: 10.1136/bmj.f1304.

引用本文的文献

The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylation and favoring T lymphocyte infiltration.胰高血糖素样肽-1受体激动剂司美格鲁肽重塑胰腺癌相关成纤维细胞，减少胶原蛋白脯氨酸羟化并促进T淋巴细胞浸润。

J Exp Clin Cancer Res. 2025 Jan 20;44(1):18. doi: 10.1186/s13046-024-03263-w.

Plant-Based Diets and Phytochemicals in the Management of Diabetes Mellitus and Prevention of Its Complications: A Review.植物性饮食和植物化学物质在糖尿病的管理和并发症的预防中的应用：综述。

Nutrients. 2024 Oct 30;16(21):3709. doi: 10.3390/nu16213709.

Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis.胰高血糖素样肽-1 受体激动剂与胰腺癌风险：一项使用 FDA 不良事件报告系统和文献可视化分析的药物警戒研究。

Int J Clin Pharm. 2023 Jun;45(3):689-697. doi: 10.1007/s11096-023-01556-2. Epub 2023 Mar 28.

The Relationship Between Dipeptidyl Peptidase-4 Inhibitor Usage and Asymptomatic Amylase Lipase Increment in Type 2 Diabetes Mellitus Patients.2型糖尿病患者使用二肽基肽酶-4抑制剂与无症状淀粉酶脂肪酶升高之间的关系

Turk J Pharm Sci. 2020 Feb;17(1):68-73. doi: 10.4274/tjps.galenos.2018.83788. Epub 2020 Feb 19.

Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks.基于肠促胰岛素的治疗对 101595 例 2 型糖尿病患者消化系统癌症的影响：一项系统评价和网络荟萃分析，结合了 84 项中位持续时间为 30 周的试验。

BMJ Open Diabetes Res Care. 2019 Sep 20;7(1):e000728. doi: 10.1136/bmjdrc-2019-000728. eCollection 2019.

Oxaliplatin reverses the GLP-1R-mediated promotion of intrahepatic cholangiocarcinoma by altering FoxO1 signaling.奥沙利铂通过改变FoxO1信号通路逆转GLP-1R介导的肝内胆管癌促进作用。

Oncol Lett. 2019 Aug;18(2):1989-1998. doi: 10.3892/ol.2019.10497. Epub 2019 Jun 19.

Pancreatic Cancer and Diabetes Mellitus.胰腺癌与糖尿病

Curr Treat Options Gastroenterol. 2018 Dec;16(4):466-478. doi: 10.1007/s11938-018-0197-8.

A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes.艾塞那肽每周一次治疗2型糖尿病的长期疗效、耐受性及安全性综述

Adv Ther. 2017 Aug;34(8):1791-1814. doi: 10.1007/s12325-017-0499-6. Epub 2017 Jul 3.

Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials.基于肠促胰岛素的疗法与2型糖尿病患者患胰腺癌的风险：一项随机对照试验的荟萃分析

Diabetes Ther. 2016 Dec;7(4):725-742. doi: 10.1007/s13300-016-0198-3. Epub 2016 Sep 21.

Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease.胰高血糖素样肽-1 类疗法在治疗非酒精性脂肪性肝病中的潜在作用。

World J Gastroenterol. 2014 Jul 21;20(27):9090-7. doi: 10.3748/wjg.v20.i27.9090.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验